Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a specialized procedure within hematology-oncology. The primary objective is twofold: to eradicate host malignancy or defective marrow through conditioning therapy and to rebuild a functional hematologic and immune system using healthy donor stem cells. Crucially, the donor immune system exerts a graft-versus-leukemia (GVL) effect, where new donor immune cells recognize and destroy residual host cancer cells.

The procedure begins with a conditioning phase lasting 4 to 10 days, administering high-dose chemotherapy with or without total body irradiation (TBI) to eliminate diseased host marrow cells and suppress host immunity. Following 1 to 2 rest days, donor stem cells are infused intravenously through a central venous catheter over 1 to 4 hours (Day 0). During the post-infusion aplastic phase (Days +1 to +21), the patient experiences total blood count depletion, requiring protective HEPA-filtered inpatient isolation, broad-spectrum prophylactic antibiotics, and frequent red blood cell and platelet transfusions. Engraftment occurs when donor cells nest in the bone marrow and achieve sustained production of functional blood cells, typically defined as an absolute neutrophil count exceeding 500 cells per microliter for three consecutive days.

Evidence-based benefits of allogeneic stem cell transplantation include:

• Curative Potential: Provides a primary curative option for high-risk or relapsed acute leukemias (NCCN Guidelines 2024).
• Graft-versus-Leukemia Effect: Donor immune T-cells continuously scan and destroy residual malignant cells, drastically reducing long-term relapse rates.
• Correction of Non-Malignant Defects: Replaces defective genetic blood lines permanently in severe aplastic anemia and hemoglobinopathies (EBMT Guidelines 2023).

Short-term recovery focuses on initial marrow reconstitution during a 3 to 5 week inpatient stay, managing side effects like oral inflammation (mucositis) and neutropenic fever. Full immunologic recovery takes 12 to 24 months. During this period, patients require daily to weekly outpatient check-ups, ongoing administration of immunosuppressive drugs to prevent graft-versus-host disease, and step-by-step childhood vaccination re-administration.

Allogeneic stem cell transplantation is indicated for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), myelofibrosis, severe aplastic anemia, severe combined immunodeficiency (SCID), sickle cell disease, and severe beta-thalassemia major.

Preparation involves comprehensive HLA tissue typing of the patient and candidate donors (matching HLA-A, -B, -C, -DRB1, and -DQB1 genes). Detailed pre-transplant workup includes echocardiogram or MUGA scan to assess cardiac ejection fraction, pulmonary function tests (DLCO), viral serologies (CMV, EBV, HIV, Hepatitis B/C), bone marrow biopsy to quantify disease burden, and surgical placement of a multi-lumen tunneled central venous catheter (Hickman catheter). Dental clearance and formal psychosocial evaluation are mandatory prior to conditioning.

Complications are categorized by onset phase. Early risks include severe neutropenic infection, mucositis, hepatic sinusoidal obstruction syndrome (SOS/VOD), and acute graft-versus-host disease (aGVHD) affecting skin, liver, or gastrointestinal tract. Late risks include chronic graft-versus-host disease (cGVHD) causing skin sclerosis, dry mucosal surfaces, and lung bronchiolitis obliterans; primary or secondary graft failure; secondary malignancies (post-transplant lymphoproliferative disorder); endocrine dysfunction; viral reactivations (cytomegalovirus, Epstein-Barr virus); and infertility.

The clinical transplant journey progresses through distinct phases: rigorous pre-transplant donor matching and organ testing; a 4 to 10 day conditioning regimen (chemotherapy with or without radiation); stem cell infusion on Day 0; a 2 to 4 week inpatient isolation period during severe blood cell suppression awaiting engraftment; and 12 to 24 months of outpatient recovery, routine infectious surveillance, and immune system monitoring.